Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
La Pharmatech Inc. operates a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The current prosecution landscape features 1 pending office action. This action is handled by 1 distinct examiner, DRAPER, LESLIE A ROYDS, who is the sole examiner identified in the portfolio. The activity is localized in a distinct art unit, which points to a concentrated technical scope for the company's pharmaceutical applications. DRAPER, LESLIE A ROYDS is the busiest examiner, overseeing the busiest examiner pending action.
For a practitioner, the presence of 1 pending office action suggests a focused stage of portfolio development. Since a distinct examiner and a distinct art unit are involved, the prosecution strategy can be optimized for the specific examination environment of DRAPER, LESLIE A ROYDS. The fact that the busiest examiner pending action is handled by this individual means that all current USPTO interactions are centralized. This streamlined profile in the Biotechnology & Pharmaceuticals sector facilitates direct management of the company's patent assets and pharmaceutical claims.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DRAPER, LESLIE A ROYDS | 1 | 27.3% | +43.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17546342 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE | DRAPER, LESLIE A ROYDS | 59d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17546342 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE | DRAPER, LESLIE A ROYDS | 59d overdue |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17546342 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE | DRAPER, LESLIE A ROYDS | 1629 | §102§103§112Other | Final Rejection | 59d overdue | Pending | Dec 09, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial